Chronic kidney disease treatment has changed significantly as researchers have developed medicines that can slow kidney function decline and reduce cardiovascular risks. Current treatment may include blood pressure management, SGLT2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists, and GLP 1 based therapies for appropriate patients.
Treatment is usually tailored according to the stage of CKD and the conditions contributing to kidney damage. Diabetes, high blood pressure, heart disease, and certain kidney disorders can all influence the treatment approach.
Common approaches include:
Regular testing can help healthcare professionals determine whether treatment is slowing disease progression.
SGLT2 inhibitors have become an important part of modern CKD management. These medicines can help slow kidney disease progression and reduce certain cardiovascular and kidney-related risks in appropriately selected patients.
Depending on the patient's circumstances, a healthcare professional may consider:
KDIGO is currently reviewing newer evidence about SGLT2 inhibitors, including their use in people with CKD who do not have type 2 diabetes.
GLP 1 receptor agonists are another important development, particularly for people who have diabetes and CKD. They can improve blood glucose control and may provide cardiovascular and kidney-related benefits in appropriate patients.
Recent evidence has prompted guideline updates concerning:
KDIGO's 2026 diabetes and CKD guideline update incorporates newer evidence on pharmacotherapy and GLP 1 receptor agonists.
For certain people with type 2 diabetes and CKD, finerenone, a nonsteroidal mineralocorticoid receptor antagonist, may be used to reduce kidney and cardiovascular risks. Potassium levels and kidney function need to be monitored because these medicines can affect potassium levels.
Current research is also examining whether this class of medicines has benefits for people with CKD who do not have diabetes. KDIGO's 2026 CKD guideline update specifically includes this question.
Medication is only one part of CKD management. Appropriate lifestyle and monitoring strategies can complement medical treatment.
Important areas include:
The best dietary and medication plan depends on kidney function and other health conditions, so generalized restrictions should not be applied without professional guidance.
When CKD progresses to kidney failure, treatment options can include dialysis or kidney transplantation for appropriate patients. Planning for these options can begin before kidney function becomes severely reduced.
Doctors may discuss:
Early planning can provide more time to understand the available choices.
The latest treatment for chronic kidney disease is not one single medicine. Modern CKD care increasingly uses combinations of therapies tailored to the person's kidney function, urine albumin levels, diabetes status, cardiovascular risks, and underlying cause. SGLT2 inhibitors have become an important kidney-protective treatment, while GLP 1 based therapies and nonsteroidal mineralocorticoid receptor antagonists are expanding the range of options for selected patients.
In 2026, KDIGO is actively updating its CKD guidance to incorporate newer evidence on these therapies, particularly for people with CKD without diabetes.
Anyone with CKD should discuss treatment choices with a qualified healthcare professional because medications, doses, and treatment combinations need to be individualized.